FGFR2 and non-small cell lung carcinoma: FGFR-Activated subtype (15.1% in stage I-III patients; 3.1% in relapsed/metastatic patients) in METex14 NSCLC was mainly characterized by FGFR1-4 overexpression, especially FGFR2 overexpression, and enrichment of FGFR signaling pathways.